OptiNose Q2 2023 Earnings Report $0.42 0.00 (-0.45%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast OptiNose EPS ResultsActual EPS$0.02Consensus EPS -$0.11Beat/MissBeat by +$0.13One Year Ago EPS-$0.23OptiNose Revenue ResultsActual Revenue$19.45 millionExpected Revenue$17.00 millionBeat/MissBeat by +$2.45 millionYoY Revenue GrowthN/AOptiNose Announcement DetailsQuarterQ2 2023Date8/10/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSEC FilingOPTN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. OptiNose Earnings HeadlinesOptinose to Present at Piper Sandler Healthcare ConferenceDecember 4, 2024 | msn.comOptinose to Present at the Piper Sandler 36th Annual Healthcare ConferenceDecember 2, 2024 | globenewswire.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 22, 2024 | Crypto Swap Profits (Ad)Former Optinose CEO Peter Miller comes out of retirement to launch new startupDecember 2, 2024 | bizjournals.comOptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price TargetNovember 16, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised GuidanceNovember 13, 2024 | finance.yahoo.comSee More OptiNose Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OptiNose? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiNose and other key companies, straight to your email. Email Address About OptiNoseOptiNose (NASDAQ:OPTN), a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.View OptiNose ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
